Our client, a world leader in developing treatments for rare genetic diseases, is seeking novel therapeutic approaches to treat the underlying causes of genetic kidney disease. Specifically, our client is interested in solutions to treat autosomal dominant polycystic kidney disease (ADPKD) and Alport syndrome, as well as cystinuria and UMOD-associated chronic kidney disease (CKD).
Approaches to treat other rare genetic kidney diseases may also be of interest provided there is high unmet need, and the solution targets the underlying mechanisms of disease...